Skip to content
Specimen Atlas of Research Peptides84 plates · MIT
← CataloguePlate IX of 84
IXPlate IXReviewed 2026-07-05

BPC-157 + TB-500 Blend

Multi-peptide blend

also known as BPC-157/TB-500, BPC + TB blend

A two-component blend that co-formulates BPC-157 and TB-500 in a single vial — a common two-component pairing. There is no published study of the combination itself; the rationale rests on each component's own literature, documented on its plate. A third-party content assay confirms what the vial contains — see the Lab verification section.

§ I

At a glance

Components
2
Total per vial
~10 mg
Combination evidence
Theoretical
Route

SQ · Reconstituted

§ II

Mechanism

Edit ↗

Primary target — Two — the actin-regulating and cytoprotective pathways of BPC-157 alongside the actin-sequestering, angiogenic pathway of TB-500.

Pathway — The blend is a co-formulation, not a single mechanism. Each component acts on its own pathway; follow the component plates for the mechanism and evidence of each..

Downstream effect — Any effect is extrapolated from the individual components; the combination has not been studied as a unit.

§ III

Dosage

Protocols described in the cited literature; not medical advice.

Edit ↗
ParameterValue
Fixed proportionThe two components share one vial in a fixed ratio, so a single draw contains both. There is no combination protocol — refer to each component's plate.
ReconstitutionOne vial, one diluent volume. The calculator's blend mode converts a chosen draw volume into each component's amount.
Evidence basisNo combination-specific data; rests on the component literature
FormLyophilized two-component vial
§ III · d

Components

A blend is a co-formulation. Each component has its own mechanism and evidence — follow its plate.

BPC-157~5 mg
TB-500~5 mg

Work out the per-component draw-volume math in the calculator’s blend mode.

§ III · c

Lab verification

Third-party lab reports tied to batch codes, re-verifiable at the issuing lab. A fact and where to re-check it — never a verdict.

Content assay
10 mg · Janoshik Analytical · 2026-04-21
§ V

Adverse events

Severities follow the FDA / CTCAE convention.

Edit ↗
Combination safetymoderate
Not studied as a combination — refer to each component's own side-effect profile
Injection sitemild
Local reactions common to subcutaneous peptide injection
Absolute contraindications
  • Active malignancy (per the component contraindications)
  • Pregnancy / breastfeeding
Relative contraindications
  • Any contraindication of BPC-157 or TB-500 individually
§ VI

Administration

Edit ↗
  1. 01
    Form

    Lyophilized blend — reconstitute with bacteriostatic water.

  2. 02
    Reconstitution

    One vial, one diluent volume. The calculator's blend mode shows each component's delivered amount per draw.

  3. 03
    Route

    Subcutaneous injection.

  4. 04
    Storage

    Reconstituted: refrigerate 2–8 °C. Lyophilized: cool, dry, out of light.

Appendix

Sources

0%

of 25 rendered claims carry a resolvable citation.

    Plate composed 2026-07-05 · maturity auto-drafted · schema v1 · Contributors: peptidesdb-core · 25 fields uncited — open contributions